These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37165836)

  • 1. KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.
    Decroos A; Cheminant M; Bruneau J; Carras S; Parinet V; Pelletier L; Lacroix L; Martin N; Giustiniani J; Lhermitte L; Asnafi V; Battistella M; Lemonnier F; De Leval L; Sicard H; Bonnafous C; Gauthier L; Genestier L; Caruso S; Gaulard P; Hermine O; Ortonne N
    Haematologica; 2023 Oct; 108(10):2830-2836. PubMed ID: 37165836
    [No Abstract]   [Full Text] [Related]  

  • 2. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial.
    Bagot M; Porcu P; Marie-Cardine A; Battistella M; William BM; Vermeer M; Whittaker S; Rotolo F; Ram-Wolff C; Khodadoust MS; Bensussan A; Paturel C; Bonnafous C; Sicard H; Azim HA; Kim YH
    Lancet Oncol; 2019 Aug; 20(8):1160-1170. PubMed ID: 31253572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma with KIR3DL2 and NKp46 expression in a human immunodeficiency virus carrier.
    Karkouche R; Ingen-Housz-Oro S; Le Gouvello S; Charlotte F; Thomas M; Zehou O; Frenkel V; Boutboul D; Chosidow O; Caumes E; Gaulard P; Ortonne N
    J Cutan Pathol; 2015 Mar; 42(3):199-205. PubMed ID: 25407699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIR3DL2 in cutaneous T-cell lymphoma: from a promising biomarker to a potential therapeutic target.
    Sun J; Wang Y
    Br J Dermatol; 2020 Jun; 182(6):1325-1326. PubMed ID: 31808144
    [No Abstract]   [Full Text] [Related]  

  • 5. Aggressive CD4-CD8-CD45RA+CCR10- Primary Cutaneous Peripheral T-cell Lymphoma, Not Otherwise Specified: A Case Report.
    Ikumi N; Fujita H; Terui T; Takahashi H; Miura K; Hatta Y; Takei M
    Acta Derm Venereol; 2019 Nov; 99(12):1176-1177. PubMed ID: 31502655
    [No Abstract]   [Full Text] [Related]  

  • 6. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting.
    Battistella M; Leboeuf C; Ram-Wolff C; Hurabielle C; Bonnafous C; Sicard H; Bensussan A; Bagot M; Janin A
    Blood; 2017 Dec; 130(26):2900-2902. PubMed ID: 29089310
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-KIR3DL2 therapy in the treatment of Sézary syndrome.
    Quaglino P
    Lancet Oncol; 2019 Aug; 20(8):1048-1049. PubMed ID: 31253571
    [No Abstract]   [Full Text] [Related]  

  • 8. Primary cutaneous peripheral T-cell lymphoma, unspecified, with CD8-positive phenotype.
    Watabe H; Kawakami T; Murakami N; Kimura S; Kannari M; Baba T; Soma Y
    Int J Dermatol; 2006 Nov; 45(11):1385-7. PubMed ID: 17076740
    [No Abstract]   [Full Text] [Related]  

  • 9. T-zone lymphoma with cutaneous involvement: a case report and review of the literature.
    Kazakov DV; Kempf W; Michaelis S; Schmid U; Cogliatti S; Dummer R; Burg G
    Br J Dermatol; 2002 Jun; 146(6):1096-100. PubMed ID: 12072087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.
    Battistella M; Janin A; Jean-Louis F; Collomb C; Leboeuf C; Sicard H; Bonnafous C; Dujardin A; Ram-Wolff C; Kadin ME; Bensussan A; Bagot M; Michel L
    Br J Dermatol; 2016 Aug; 175(2):325-33. PubMed ID: 27037558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report.
    Piekarz RL; Robey R; Sandor V; Bakke S; Wilson WH; Dahmoush L; Kingma DM; Turner ML; Altemus R; Bates SE
    Blood; 2001 Nov; 98(9):2865-8. PubMed ID: 11675364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma.
    Van Der Weyden C; Bagot M; Neeson P; Darcy PK; Prince HM
    Expert Opin Investig Drugs; 2018 Aug; 27(8):691-697. PubMed ID: 30001170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):180-5. PubMed ID: 22521504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IPH4102, a humanized KIR3DL2 antibody with potent activity against cutaneous T-cell lymphoma.
    Marie-Cardine A; Viaud N; Thonnart N; Joly R; Chanteux S; Gauthier L; Bonnafous C; Rossi B; Bléry M; Paturel C; Bensussan A; Bagot M; Sicard H
    Cancer Res; 2014 Nov; 74(21):6060-70. PubMed ID: 25361998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas.
    Feldman AL; Law M; Remstein ED; Macon WR; Erickson LA; Grogg KL; Kurtin PJ; Dogan A
    Leukemia; 2009 Mar; 23(3):574-80. PubMed ID: 18987657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell receptor gene rearrangement analysis: cutaneous T cell lymphoma, peripheral T cell lymphoma, and premalignant and benign cutaneous lymphoproliferative disorders.
    Zelickson BD; Peters MS; Muller SA; Thibodeau SN; Lust JA; Quam LM; Pittelkow MR
    J Am Acad Dermatol; 1991 Nov; 25(5 Pt 1):787-96. PubMed ID: 1839392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
    Woo S; Gardner ER; Chen X; Ockers SB; Baum CE; Sissung TM; Price DK; Frye R; Piekarz RL; Bates SE; Figg WD
    Clin Cancer Res; 2009 Feb; 15(4):1496-503. PubMed ID: 19228751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.
    Wang L; Rocas D; Dalle S; Sako N; Pelletier L; Martin N; Dupuy A; Tazi N; Balme B; Vergier B; Beylot-Barry M; Carlotti A; Bagot M; Battistella M; Chaby G; Ingen-Housz-Oro S; Gaulard P; Ortonne N
    Br J Dermatol; 2022 Dec; 187(6):970-980. PubMed ID: 35895386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.